Viewing nowCombinationJanudam M Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.

MFDS item code 202200207 · Approved 2022.01.12 · Insurance code 694004030
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct when blood sugar control is difficult for patients with type 2 diabetes using dietary restrictions and exercise alone. It is particularly helpful for individuals who have not previously received diabetes medication therapy and find it challenging to control blood sugar levels with monotherapy. Additionally, if blood sugar control is insufficient when taking metformin or sitagliptin alone, this medication can be used to switch treatments or for combination therapy. It can also enhance blood sugar control when used in conjunction with metformin and sulfonylurea, or metformin and thiazolidinedione if their combination is inadequate. If blood sugar control remains poor after using insulin and metformin, this medication may assist in treating by combining with insulin. Thus, it is employed to improve blood sugar control based on the patient's condition and existing treatment.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial metformin dose should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin, diabetes treatment agents; therefore, several precautions must be adhered to while taking it. First, serious allergic reactions may occur during the use of this medication, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a physician. Additionally, there is a risk of developing acute pancreatitis, which causes inflammation of the pancreas, so if experiencing severe abdominal pain, vomiting, or fever, visit a hospital immediately. This medication should not be taken by patients with poor kidney function, acute heart disease, severe infections, or specific diseases; pregnant or breastfeeding women should also avoid it. Regular kidney function tests must be performed during use, and if kidney function rapidly declines, temporarily discontinue use of the medication. Moreover, the metformin component included in this medication can rarely lead to serious metabolic abnormalities known as lactic acidosis, so caution is required in cases of severe dehydration, excessive alcohol consumption, or severe infections. While using this medication, if meal quantities are irregular or physical activity increases suddenly, hypoglycemic symptoms may appear; therefore, blood sugar levels should be checked frequently, and attention should be paid to hypoglycemic symptoms. Furthermore, when used with other hypoglycemic agents or alcohol, the risk of hypoglycemia may increase, so inform healthcare providers about any other medications or alcohol use. Patients scheduled for surgery should stop taking this medication 48 hours prior to surgery and resume only after confirming normal kidney function post-surgery. Finally, gastrointestinal disturbances (diarrhea, nausea, vomiting, etc.), headaches, and upper respiratory tract infections may occur during the use of this medication; consult healthcare providers if symptoms worsen.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight, sealed container, and it is advisable to keep it at room temperature between 1 and 30 degrees Celsius. This storage method will help maintain the drug's effectiveness and prevent degradation.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.